Biochemistry

   

Convergence Revolution – Piloting the Third Scientific Revolution Through Start-Ups for Breast Cancer Cure

Authors: Pramod Khargonekar, Anthony Sinskey, Charles Miller, Balu Ranganathan

Convergence revolution integrates various academic disciplines with wide spectrum of activities and also connects them with translation and innovation ecosystem thereby going well beyond traditional collaborations. This is the third revolution in the life science arena, first being DNA discovery and second genomics where almost entire human genome has been sequenced. The third revolution, convergence revolution has the potential to lead to a solution for breast cancer cure. Breast cancer is the second largest mortality causative agent among women. In United States, nearly 40,000 women die of breast cancer every year. Till date (March 2017), 3.1 million women have been medicated for breast cancer. On an average every 2 minutes, a woman in the U.S. is diagnosed with breast cancer. Convergence may provide a more effective solution for cure breast cancer by multipronged approach using nanotechnology (targeted delivery with controlled release), imaging protocols (Raman spectroscopy) and biomarkers detection involving physicists, chemists, bioengineers, radiologists, clinical oncologists and entrepreneurs and proposing for a National Cancer Data Ecosystem. This work is a classic example of convergence involving multi-disciplinary researchers and technology developers. Several start-ups are working in the direction of breast cancer therapy onto clinical trials which can pave way for translation to clinics for the cure of belligerent types of breast cancers which affect young women. You can submit your Manuscripts at:  https://symbiosisonlinepublishing.com/submitManuscript.php 

Comments: 6 Pages.

Download: PDF

Submission history

[v1] 2017-08-26 02:22:48

Unique-IP document downloads: 1 times

Vixra.org is a pre-print repository rather than a journal. Articles hosted may not yet have been verified by peer-review and should be treated as preliminary. In particular, anything that appears to include financial or legal advice or proposed medical treatments should be treated with due caution. Vixra.org will not be responsible for any consequences of actions that result from any form of use of any documents on this website.

Add your own feedback and questions here:
You are equally welcome to be positive or negative about any paper but please be polite. If you are being critical you must mention at least one specific error, otherwise your comment will be deleted as unhelpful.

comments powered by Disqus